The American Society of Cataract and Refractive Surgery convened a CyPass Withdrawal Task Force to review the data from the COMPASS-XT study and related research and develop an independent physician guidance document associated with the voluntary withdrawal of Alcon’s CyPass Micro-Stent. Today the Task Force released its Preliminary ASCRS CyPass Withdrawal Consensus Statement.
The task force, comprised of ASCRS Clinical Committee leaders specializing in glaucoma and cornea, conducted an independent evaluation of the data and release an objective summation of its findings. Published as a guidance document, the report summarizes the data, provides preliminary clinical recommendations regarding monitoring corneal health, and includes suggestions for managing patients with indwelling CyPass devices.
The ASCRS document follows the September 14, 2018 FDA Safety Communication Statement.
Further details on the results of the 5-year follow-up study of the CyPass Micro-Stent along with additional resources are available at www.alcon.com/CyPass.